Publications by authors named "Hugues DeLavallade"
Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys).
Leuk Res Rep
December 2022
Article Synopsis
- Pegylated interferons, particularly peginterferon alfa-2a, are commonly used to treat Myeloproliferative Neoplasms (MPN), but a newer drug called ropeginterferon alfa-2b (ropegIFN) has emerged as an option, especially for Polycythaemia Vera (PV).
- RopegIFN received a recommendation from the European Medicine Authority (EMA) and FDA approval in November 2021 after positive results from Phase III trials.
- The study highlights the safety and tolerability of ropegIFN in MPN patients, confirming its efficacy in treating PV and its potential use during pregnancy.
The seasonal influenza A vaccine is recommended for patients with myeloproliferative neoplasms (MPNs). We hypothesised that immune deregulation associated with MPNs may affect the immune response gained following vaccinations when compared to healthy controls. Using deep immunophenotyping with high-dimensional single-cell analysis and mass cytometry we could demonstrate an altered immune response in MPN patients following vaccination.
View Article and Find Full Text PDFNatural killer (NK) cells exert antimyeloma cytotoxicity. The balance between inhibition and activation of NK-cells played by the inherited repertoire of killer immunoglobulin-like receptor (KIR) genes therefore may influence prognosis. One hundred eighty-two patients with multiple myeloma (MM) were analyzed for KIR repertoire.
View Article and Find Full Text PDF